AstraZeneca: IMFINZI Significantly Improved Event-Free Survival In AEGEAN Phase III Trial For Patients With Resectable Non-Small Cell Lung Cancer
March 10, 2023
March 10, 2023
WILMINGTON, Delaware, March 10 (TNSres)-- AstraZeneca, a biopharmaceutical company, issued the following news release on March 9, 2023:
Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo-controlled trial showed that treatment with AstraZeneca's IMFINZI(R) (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improve . . .
Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo-controlled trial showed that treatment with AstraZeneca's IMFINZI(R) (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improve . . .